CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness.
NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
表达嵌合抗原受体的T细胞(CAR-T)过继转移可有效治疗部分难治性血液系统恶性肿瘤患者,但体内T细胞扩增和持续存在能力差可能限制疗效。较低分化状态的T细胞与CAR-T 增殖及介导抗肿瘤应答的能力相关;在体外生产过程中限制肿瘤特异性T细胞分化的干预可增强疗效。NOTCH信号参与多种细胞谱系的命运决定;研究显示,在记忆性CD8+ T细胞中,NOTCH可上调转录因子FOXM1、减轻分化并增强体内增殖及抗肿瘤效果。
本研究使用无细胞培养体系,在初始CD4+ T细胞活化及CAR-T 制备时提供激动性NOTCH1信号,并考察其对分化、转录因子表达、细胞因子生成和肿瘤应答的影响。NOTCH1激动可有效在初始但非记忆性CD4+ T细胞来源的CAR-T 中诱导干细胞记忆表型,并上调AhR和c-MAF表达,驱动白细胞介素22、白细胞介素10和颗粒酶B生成增加。NOTCH1激动的CD4+ CAR-T 抗原应答增强,在携带人淋巴瘤异种移植的小鼠中扩增至显著更高水平。NOTCH1激动的CD4+ CAR-T 还可为共同转移的CD8+ CAR-T 提供更强辅助,使其扩增改善,并在低CAR-T 剂量下于体内产生治愈性抗肿瘤应答。
我们的数据扩展了NOTCH塑造CD4+ T细胞行为机制的认识,并表明在体外基因改造过程中激活NOTCH1信号,可能增强表达肿瘤靶向受体的工程化T细胞功能。
Adoptive transfer of T cells expressing chimeric antigen receptors (CAR-T) effectively treats refractory hematologic malignancies in a subset of patients but can be limited by poor T-cell expansion and persistence in vivo. Less differentiated T-cell states correlate with the capacity of CAR-T to proliferate and mediate antitumor responses, and interventions that limit tumor-specific T-cell differentiation during ex vivo manufacturing enhance efficacy.
NOTCH signaling is involved in fate decisions across diverse cell lineages and in memory CD8+ T cells was reported to upregulate the transcription factor FOXM1, attenuate differentiation, and enhance proliferation and antitumor efficacy in vivo.
Here, we used a cell-free culture system to provide an agonistic NOTCH1 signal during na ve CD4+ T-cell activation and CAR-T production and studied the effects on differentiation, transcription factor expression, cytokine production, and responses to tumor. NOTCH1 agonism efficiently induced a stem cell memory phenotype in CAR-T derived from na ve but not memory CD4+ T cells and upregulated expression of AhR and c-MAF, driving heightened production of interleukin-22, interleukin-10, and granzyme B.
NOTCH1-agonized CD4+ CAR-T demonstrated enhanced antigen responsiveness and proliferated to strikingly higher frequencies in mice bearing human lymphoma xenografts. NOTCH1-agonized CD4+ CAR-T also provided superior help to cotransferred CD8+ CAR-T, driving improved expansion and curative antitumor responses in vivo at low CAR-T doses.
Our data expand the mechanisms by which NOTCH can shape CD4+ T-cell behavior and demonstrate that activating NOTCH1 signaling during genetic modification ex vivo is a potential strategy for enhancing the function of T cells engineered with tumor-targeting receptors.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。